Literature DB >> 31610197

Investigating curcumin potential for diabetes cell therapy, in vitro and in vivo study.

Mohammad Amin Javidi1, Ayat Kaeidi2, Seyedeh Sahar Mortazavi Farsani1, Sadegh Babashah1, Majid Sadeghizadeh3.   

Abstract

AIMS: An important obstacle on the way of cell-based therapy is the risk of tumorigenicity in the patients benefit from these transplanted cells due to undifferentiated cells which participate in transplantation. Curcumin, the main compound of spice turmeric -as one of the natural products-was demonstrated to possess effective anti-cancer properties, with no significant effect on normal cells in dose and/or time-dependent manner. Furthermore many studies have been accomplished using curcumin for diabetes treatment. Therefore in this study we examined the efficacy of IPCs treated with curcumin in vivo. MAIN
METHODS: Differentiation efficiency investigated by flowcytometry. RNA extraction and real-time PCR performed for important genes in IPC differentiation and tumorigenesis including Insulin, Nestin, Ngn3, Pdx1, P21, and P53. Finally we investigated the efficiency of these differentiated and treated cells in diabetic rats. KEY
FINDINGS: Our data indicates that nanocurcumin -in a specific dose-reduces the expression of Nestin with no significant effect on insulin expression in mRNA and protein level. Besides blood glucose level of diabetic rats which treated with DNC + cells, decreased from average 350 (mg/dI) to 100 (mg/dI). Checking out the pancreases of these rats, demonstrated that their endocrine segment was rebuilt. Moreover hematoxylin & eosin staining and IF results revealed that the Langerhans Islands were reformed. SIGNIFICANCE: IPCs' which treated with DNC were able to efficiently control the blood glucose level in diabetic rats which these cells were transplanted to them. Hence Curcumin has the potential to be employed in this kind of cell therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes type I model rats; IPCs; MSCs; Nanocurcumin; Regenerative medicine

Mesh:

Substances:

Year:  2019        PMID: 31610197     DOI: 10.1016/j.lfs.2019.116908

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

Review 1.  Research in the Middle East into the Health Benefits of Curcumin.

Authors:  Paul C Guest; Amirhosein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  How Curcumin Targets Inflammatory Mediators in Diabetes: Therapeutic Insights and Possible Solutions.

Authors:  Yaseen Hussain; Haroon Khan; Ghallab Alotaibi; Fazlullah Khan; Waqas Alam; Michael Aschner; Philippe Jeandet; Luciano Saso
Journal:  Molecules       Date:  2022-06-24       Impact factor: 4.927

3.  Curcumin Inhibits Hyperandrogen-Induced IRE1α-XBP1 Pathway Activation by Activating the PI3K/AKT Signaling in Ovarian Granulosa Cells of PCOS Model Rats.

Authors:  Yaling Zhang; Lei Wang; Yajing Weng; Daojuan Wang; Rong Wang; Hongwei Wang; Lihui Wang; Shanmei Shen; Hongwei Wang; Yan Li; Yong Wang
Journal:  Oxid Med Cell Longev       Date:  2022-08-24       Impact factor: 7.310

4.  Dietary supplementation with curcumin-loaded nanocapsules in lambs: Nanotechnology as a new tool for nutrition.

Authors:  Hiam Marcon; Luiz G Griss; Vitor L Molosse; Bruno G O Cecere; Davi F Alba; Karoline W Leal; Gabriela M Galli; Carine F Souza; Matheus D Baldissera; Samanta Gundel; Vitória de A Bassotto; Aline F Ourique; Marcelo Vedovatto; Aleksandro S Da Silva
Journal:  Anim Nutr       Date:  2021-03-17

Review 5.  Therapeutic potential of curcumin in diabetic retinopathy (Review).

Authors:  Jian Yang; Xiao Miao; Feng-Juan Yang; Jin-Feng Cao; Xin Liu; Jin-Ling Fu; Guan-Fang Su
Journal:  Int J Mol Med       Date:  2021-03-11       Impact factor: 4.101

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.